We are live on ! Find out more
ASBPW

Aspire Biopharma Warrant
ASBPW

39 hedge funds and large institutions have $726K invested in Aspire Biopharma Warrant in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

3% less funds holding

Funds holding: 40 → 39 (-1)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

37% less capital invested

Capital invested by funds: $1.15M → $726K (-$426K)

Holders
39
Holders Change
-1
Holders Change %
-2.5%
% of All Funds
0.62%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
3
Reduced
4
Closed
3
Calls
$2.36M
Puts
–
Net Calls
+$2.36M
Net Calls Change
+$234K

Top Buyers

Rank Fund Capital Flow
1
FSI
Flow State Investments
Illinois
+$2.92K
2
MC
Meteora Capital
Florida
+$2.02K
3
Walleye Capital
Walleye Capital
New York
+$1.18K
4
Walleye Trading
Walleye Trading
New York
+$661
5
UBS Group
UBS Group
Switzerland
+$37

Top Sellers

Rank Fund Capital Flow
1
MP
Mangrove Partners
Connecticut
-$652K
2
KC
Kepos Capital
New York
-$18K
3
LCM
Landscape Capital Management
New Jersey
-$751
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$612
5
AC
Athos Capital
Hong Kong
-$292
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Athos Capital
Hong Kong
$232K -$292 -3,616 -14%
PC
2
Periscope Capital
Ontario, Canada
$74.1K – – –
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$53.2K – – –
SCM
4
Saba Capital Management
New York
$49.9K – – –
LA
5
Linden Advisors
New York
$44.6K – – –
AA
6
AQR Arbitrage
Connecticut
$32.4K – – –
HCM
7
Highbridge Capital Management
New York
$27.4K – – –
SC
8
Sculptor Capital
New York
$24.8K – – –
Verition Fund Management
9
Verition Fund Management
Connecticut
$21.6K – – –
WAM
10
Wolverine Asset Management
Illinois
$20.4K – – –
Barclays
11
Barclays
United Kingdom
$17.7K – – –
TCA
12
Taconic Capital Advisors
New York
$15K – – –
Nomura Holdings
13
Nomura Holdings
Japan
$10.9K – – –
D.E. Shaw & Co
14
D.E. Shaw & Co
New York
$10K – – –
SFM
15
Spartan Fund Management
Canada
$9.35K -$146 -1,804 -1%
CCM
16
Context Capital Management
California
$9K – – –
RCM
17
Radcliffe Capital Management
Pennsylvania
$8.12K – – –
SRCM
18
Sage Rock Capital Management
New York
$8.12K – – –
PAMP
19
Polar Asset Management Partners
Ontario, Canada
$7.02K – – –
LP
20
LMR Partners
United Kingdom
$6.34K – – –
WA
21
Whitebox Advisors
Minnesota
$6.34K – – –
HIM
22
HGC Investment Management
Ontario, Canada
$5.07K – – –
KL
23
KIM LLC
Kansas
$5K – – –
FSI
24
Flow State Investments
Illinois
$4.88K +$2.92K +36,168 +60%
CCM
25
CAAS Capital Management
New York
$3.8K – – –
1
2

ASBPW Hedge Fund Activity: Q3 2023 in Review

39 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma Warrant (ASBPW) for Q3 2023, worth a combined $726K — down 37% from $1.15M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of ASBPW and 2 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 3 added.

The largest buyer was Flow State Investments, adding an estimated $2.92K. The largest seller was Mangrove Partners, exiting entirely with an estimated $652K sold.

  • 39 institutional investors held Aspire Biopharma Warrant (ASBPW) as of Q3 2023, down from 40 in Q2 2023.
  • Funds reported $726K of Aspire Biopharma Warrant stock for Q3 2023, down 37% quarter-over-quarter.
  • 2 funds opened new Aspire Biopharma Warrant positions in Q3 2023 and 3 closed out, a net change of -1 holder.
  • The largest Aspire Biopharma Warrant buyer in Q3 2023 was Flow State Investments, an estimated $2.92K added.
  • The largest Aspire Biopharma Warrant seller in Q3 2023 was Mangrove Partners, an estimated $652K sold.

Based on aggregated 13F filings for Q3 2023.